Market Overview

Atypical Hemolytic Uremic Syndrome - A Drug Pipeline Analysis Report 2018 - Technavio

Share:

Technavio has announced their latest pipeline analysis report on the
drug pipeline for the atypical
hemolytic uremic syndrome
. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period to treat the atypical hemolytic uremic
syndrome.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180813005236/en/

Technavio has published a new report on the drug development pipeline for atypical hemolytic uremic  ...

Technavio has published a new report on the drug development pipeline for atypical hemolytic uremic syndrome, including a detailed study of the pipeline molecules. (Photo: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Atypical hemolytic uremic syndrome: Market
overview

Atypical hemolytic uremic syndrome (aHUS) is a systemic disease that
primarily affects the kidneys. This rare condition is associated with
genetic mutations or polymorphisms that result in chronic, uncontrolled
activation of the alternative complement pathway. It is a syndrome
characterized by three major problem areas, namely progressive renal
failure, problems associated with red blood cell and platelet counts,
and problems that occur in the vascular system. aHUS are not caused by
external agents such as bacteria or virus. Some internal chain of events
set the disease off, and the syndrome becomes active. The syndrome is
not well understood. In many cases, it has been identified as a genetic
problem due to an irregularity in several suspect genes.

According to a senior market research analyst at Technavio, "Most of
the cases of aHUS are sporadic, which means they occur in people with no
apparent history of the disorder in the family. Less than 20% of all
cases have been reported to run in families. When the disorder is
familial, it can have an autosomal dominant or autosomal recessive
pattern of inheritance."

Atypical hemolytic uremic syndrome:
Segmentation analysis

This pipeline analysis report segments the atypical hemolytic uremic
syndrome market based on therapies employed (monotherapy), RoA
(subcutaneous, oral, intravenous+subcutaneous, and intravenous),
therapeutic modality (monoclonal antibody, small molecule, recombinant
protein, siRNA oligonucleotide, and peptide), targets (complement C5,
complement factor H, complement C5a, and complement C5a receptor), MoA
(complement C5 inhibitor, complement factor H replacement, complement
C5a inhibitor, and complement C5a receptor antagonist), geographical
segmentation (US, Europe, Japan, Canada, Australia, and Korea) and
recruitment status (completed and recruiting). It provides an in-depth
analysis of the prominent factors influencing the market, including
drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 36% of the molecules that are
being investigated for the treatment of atypical hemolytic uremic
syndrome are monoclonal antibodies.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!